bs-0480R-APC-Cy7 Search Results


ifnγ  (Bioss)
90
Bioss ifnγ
Lung metastasis in the LM8‐inoculated mice
Ifnγ, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ifnγ/product/Bioss
Average 90 stars, based on 1 article reviews
ifnγ - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ifn gamma polyclonal antibody, apc-cy7 conjugated  (Bioss)
N/A
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and
   Buy from Supplier

Image Search Results


Lung metastasis in the LM8‐inoculated mice

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Lung metastasis in the LM8‐inoculated mice

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques:

Effect of IFNγ and CD40L (Comb) gene‐transfection on DC‐based therapy. (A) Survival of mice with the indicated treatments. (B) The relative tumor volume (with the volume on day 0 set at 1) of each mouse in the control groups. Black solid lines indicate the relative tumor volumes of the [Untreated] group; black dotted lines indicate those of the [Cont (IT)] group; gray solid lines indicate those of the [Cont (IV)] group. (C) The relative tumor volume of each mouse in the intratumoral (IT) gene‐administrated group. Black solid lines indicate relative tumor volumes of the [Comb (IT) +DC] group. Black dotted lines indicate those of the [Comb (IT)] group. Gray solid lines indicate those of the [Cont (IT) + DC] group. (D) The relative tumor volume of each mouse in the intravenous (IV) gene‐administrated group. Black solid lines indicate relative tumor volumes of the [Comb (IV) +DC] group. Black dotted lines indicate those of the [Comb (IV)] group. Gray solid lines indicate those of the [Cont (IV) + DC] group. Experiments were performed independently three times using a total of six mice in each group. All mice were humanely euthanized according to the criteria in Section . * P < .05, vs the [Cont (IT)] group. ** P < .05 vs the [Untreated] group, and P < .01, vs the [Cont (IV)] group. *** P < .05 vs the [Untreated] group, and P < .005, vs the [Cont (IT) +DC] group or the [Cont (IV) +DC] group, respectively

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of IFNγ and CD40L (Comb) gene‐transfection on DC‐based therapy. (A) Survival of mice with the indicated treatments. (B) The relative tumor volume (with the volume on day 0 set at 1) of each mouse in the control groups. Black solid lines indicate the relative tumor volumes of the [Untreated] group; black dotted lines indicate those of the [Cont (IT)] group; gray solid lines indicate those of the [Cont (IV)] group. (C) The relative tumor volume of each mouse in the intratumoral (IT) gene‐administrated group. Black solid lines indicate relative tumor volumes of the [Comb (IT) +DC] group. Black dotted lines indicate those of the [Comb (IT)] group. Gray solid lines indicate those of the [Cont (IT) + DC] group. (D) The relative tumor volume of each mouse in the intravenous (IV) gene‐administrated group. Black solid lines indicate relative tumor volumes of the [Comb (IV) +DC] group. Black dotted lines indicate those of the [Comb (IV)] group. Gray solid lines indicate those of the [Cont (IV) + DC] group. Experiments were performed independently three times using a total of six mice in each group. All mice were humanely euthanized according to the criteria in Section . * P < .05, vs the [Cont (IT)] group. ** P < .05 vs the [Untreated] group, and P < .01, vs the [Cont (IV)] group. *** P < .05 vs the [Untreated] group, and P < .005, vs the [Cont (IT) +DC] group or the [Cont (IV) +DC] group, respectively

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection

Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on the infiltration of CD8 + cells into LM8 tumors. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. Immunohistochemistry was performed to detect CD8 + cells present in the tumor tissue. (A) Typical photos of tumors collected from the indicated treatment groups are shown. Expression of CD8 is shown as brown color products. (B) Counts of CD8 + cells in 1000 cells in tumors are shown. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on the infiltration of CD8 + cells into LM8 tumors. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. Immunohistochemistry was performed to detect CD8 + cells present in the tumor tissue. (A) Typical photos of tumors collected from the indicated treatment groups are shown. Expression of CD8 is shown as brown color products. (B) Counts of CD8 + cells in 1000 cells in tumors are shown. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection, Immunohistochemistry, Expressing

Effect of the IFNγ and CD40L (Comb) gene‐transfection therapy on tumor‐infiltrating cells. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. The Iba 1 + activated macrophage and granzyme B + killer cells in the tumor tissue were detected by immunohistochemistry. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of the IFNγ and CD40L (Comb) gene‐transfection therapy on tumor‐infiltrating cells. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. The Iba 1 + activated macrophage and granzyme B + killer cells in the tumor tissue were detected by immunohistochemistry. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection, Immunohistochemistry

Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on tumor‐infiltrating cells. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. Mature DCs (MHC II high CD83 + cells), MDSCs (CD11b + , Gr1 + cells), NK (NK1.1 + ) cells and PD‐L1 + cells in the tumor tissues were detected in FCM. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on tumor‐infiltrating cells. Tumor tissue was collected from mice with the indicated treatments at 7 d after the second treatment. Mature DCs (MHC II high CD83 + cells), MDSCs (CD11b + , Gr1 + cells), NK (NK1.1 + ) cells and PD‐L1 + cells in the tumor tissues were detected in FCM. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection

Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on systemic immune responses. Spleen cells were collected from the LM8 tumor‐bearing mice with the indicated treatments at 7 d after the second treatment. Cytotoxic activity of the cells against LM8 (A), BW5147 (B), and YAC‐1 (C) was evaluated in vitro. The experiments were repeated twice. Each experiment was performed using three mice in each treatment group. A typical result is shown. All mice were humanely euthanized according to the criteria in Section . Results are expressed as mean ± SE. * P < .05, ** P < .01 vs the [Untreated] group, † P < .05 vs the [Comb (IT) + DC] and [Comb (IV)] group at the E/T ratio

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on systemic immune responses. Spleen cells were collected from the LM8 tumor‐bearing mice with the indicated treatments at 7 d after the second treatment. Cytotoxic activity of the cells against LM8 (A), BW5147 (B), and YAC‐1 (C) was evaluated in vitro. The experiments were repeated twice. Each experiment was performed using three mice in each treatment group. A typical result is shown. All mice were humanely euthanized according to the criteria in Section . Results are expressed as mean ± SE. * P < .05, ** P < .01 vs the [Untreated] group, † P < .05 vs the [Comb (IT) + DC] and [Comb (IV)] group at the E/T ratio

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection, Activity Assay, In Vitro

Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on spleen cells. Spleen was collected from mice with the indicated treatments at 7 days after the second treatment. Mature DCs (MHC II high CD83 + cells), MDSCs (CD11b + , Gr1 + cells), NK (NK1.1 + ) cells and PDL‐1 + cells in the tumor tissues were detected in FCM. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Journal: FASEB bioAdvances

Article Title: Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell‐based immunotherapy

doi: 10.1096/fba.2019-00052

Figure Lengend Snippet: Effect of IFNγ and CD40L (Comb) gene‐transfection therapy on spleen cells. Spleen was collected from mice with the indicated treatments at 7 days after the second treatment. Mature DCs (MHC II high CD83 + cells), MDSCs (CD11b + , Gr1 + cells), NK (NK1.1 + ) cells and PDL‐1 + cells in the tumor tissues were detected in FCM. Results are expressed as mean ± SE. The experiment was performed using three mice in each treatment group. All mice were humanely euthanized according to the criteria in Section . * P < .05, ** P < .01 by the Tukey‐Kramer test

Article Snippet: Cells infiltrating tumor tissues were evaluated by immunohistochemistry using following primary Abs: for IFNγ, Bioss Cat# bs‐0480R‐PE‐Cy7, RRID:AB_11092092; for CD40L, Biorbyt Cat# orb10326, RRID:AB_10746923; for CD8, clone 53‐6.7, Thermo Fisher Scientific Cat# 14‐0081‐81, RRID:AB_467086; for Foxp3, clone FJK‐16s, Thermo Fisher Scientific Cat# 14‐5773‐80, RRID:AB_467575; for Iba1, Wako Pure Chemical Industries Inc, Cat# 019‐19741, RRID:AB_839504; for granzyme B, Spring Bioscience Cat# E2580, RRID:AB_1661202.

Techniques: Transfection